Emprumapimod clinical trials
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses emprumapimod is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2008 (4)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 4 |
| 2011 | 1 |
| 2014 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Pfizer (6) · Array Biopharma, now a wholly owned subsidiary of Pfizer (2)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses emprumapimod is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Study To Evaluate The Pharmacokinetics, Excretion, Mass Balance and Metabolism of PF-07265803CompletedPhase 1PfizerNCT05286281Written as PF-07265803
- A Safety Study of ARRY-371797 in Healthy SubjectsCompletedPhase 1Array Biopharma, now a wholly owned subsidiary of PfizerNCT00790049Written as ARRY-371797, p38 inhibitor; oral
- A Study of ARRY-371797 in Subjects Undergoing Third Molar ExtractionCompletedPhase 2PfizerNCT00542035Written as ARRY-371797, p38 inhibitor; oral
- A Study of ARRY-371797 in Subjects Undergoing Third Molar ExtractionCompletedPhase 2PfizerNCT00663767Written as ARRY-371797, p38 inhibitor; oral
- A Study of ARRY-371797 in Patients With Active Ankylosing SpondylitisTerminatedPhase 2PfizerNCT00811499Written as ARRY-371797, p38 inhibitor; oral
- A Study of ARRY-371797 in Patients With Osteoarthritis of the KneeCompletedPhase 2PfizerNCT01366014Written as ARRY-371797, p38 inhibitor; oral
- A Study of ARRY-371797 in Patients With LMNA-Related Dilated CardiomyopathyCompletedPhase 2PfizerNCT02057341Written as ARRY-371797, p38 inhibitor; oral
- A Study of ARRY-371797 in Patients With Rheumatoid ArthritisCompletedPhase 1Array Biopharma, now a wholly owned subsidiary of PfizerNCT00729209Written as ARRY-371797, p38 inhibitor; oral
Codes
What other systems call emprumapimod · ClinicalTrials.gg INT014880
- UNII (FDA) 4JG61K4659EMPRUMAPIMODOne source FDA
- NCI Thesaurus C184878EmprumapimodOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 4JG61K4659 | EMPRUMAPIMOD | One source FDA |
| NCI Thesaurus | C184878 | Emprumapimod | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.